Treatment of advanced breast cancer: Current status

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 2, 1996, Pages 5-7

  Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

anthracyclines; docetaxel (Taxotere ); drug resistance; metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DOCETAXEL; FLUOROURACIL; MITOMYCIN C; PACLITAXEL; VINCA ALKALOID;

ADVANCED CANCER; BREAST CANCER; CONFERENCE PAPER; FEMALE; HORMONAL THERAPY; HUMAN; METASTASIS; PRIORITY JOURNAL;

EID: 0029813044     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608002-00002     Document Type: Conference Paper

References (15)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA 1995; 45: 8-30.
2. Leonard RCF, Rodger A, Dixon JM. Metastatic breast cancer. BMJ 1994; 309: 1501-1504.
3. Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 391: 1552-1562.
4. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al., eds. Breast diseases(2nd edition). Philadelphia, PA: Lippincott; 1991: 604-665.
5. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44 (suppl 4): 17-28.
6. Hortobagyi GN, Smith TL, Legha SS, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1993; 1: 776-786.
7. Norton L. Salvage chemotherapy of breast cancer. Semin Oncol 1994; 21 (suppl 7): 19-24.
8. Flamm Honig S. Treatment of metastatic disease: hormonal therapy and chemotherapy. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast; 1996: 669-734.
9. Pokka K, Bloomquist C, Rissanen P et al. Salvage therapies in women who fail to respond to first line treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer. J Clin Oncol 1994; 12: 1639-1647.
10. Ravdin PM, Valero V. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol 1995; 22 (suppl 4): 17-21.
11. Henderson IC, Allegra JC, Woodcock T, et al. Randomized trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560-571.
12. Clavel M, Cativel G. Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer 1993; 29A: 598-604.
13. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment for Cancer. J Clin Oncol 1995, 13: 314-322.
14. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13; 2879-2885.
15. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-2894.